

28 April 2025

**SkinBioTherapeutics plc**  
("SkinBioTherapeutics" or "the Company")

**Warrant Exercise Notice and Total Voting Rights**

SkinBioTherapeutics plc, (AIM: SBTX, or the "Company"), the life science business focused on skin health, announces that it received an Exercise Notice from Macquarie ("Macquarie") for 1,099,244 ordinary shares in SkinBioTherapeutics plc at £0.2043 per share.

Following the above exercise, no outstanding warrants remain with Macquarie.

**Admission and Total Voting Rights**

Application has been made for the 1,099,244 new ordinary shares, which will rank pari passu in all respects with the existing ordinary shares of the Company, to be admitted to AIM, which is expected to occur on or around 8.00 a.m. on 1 May 2025 ("Admission"). Upon Admission, the total number of issued shares and the total number of voting rights in the Company will be 234,074,627.

The above figure of 234,074,627 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

-Ends-

*The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.*

**For more information please contact:**

<b>SkinBioTherapeutics plc</b>	<b>+44 (0) 191 495 7325</b>
Martin Hunt, Chair	
Stuart J. Ashman, CEO	

<b>Cavendish Capital Markets Limited</b>	<b>+44 (0) 20 7220 0500</b>
<b>(Nominated Adviser &amp; Broker)</b>	
Giles Balleny, Dan Hodgkinson (Corporate Finance)	
Charlie Combe (Broking)	
Dale Bellis (Sales)	

<b>Vigo Consulting (financial press)</b>	<b>+44 (0) 20 7390 0230</b>
Rozi Morris	SkinBio@vigoconsulting.com

**Notes to Editors**

**About SkinBioTherapeutics plc**

SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester.

The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix) and food supplements to modulate the immune system by harnessing the gut-skin axis (AxisBiotix). The cosmetic pillar has a partnership with Croda plc and the SkinBiotix active ingredient, Zenakine™ was launched in April 2025. The Group's first in-house product, AxisBiotix-Ps™, is a food supplement to address the symptoms of mild to moderate psoriasis.

The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skin care and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: [www.skinbiotherapeutics.com](http://www.skinbiotherapeutics.com).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

IOEBLGDSBUDDGUR